Traws Pharma (TRAW) Operating Expenses (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Operating Expenses of $6.9 million for Q1 2026, up 32.05% year-over-year from $5.3 million in Q1 2025, and down 5.73% quarter-over-quarter from $7.4 million in Q4 2025.
Traws Pharma (TRAW) Operating Expenses (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Operating Expenses for 15 consecutive years, with $6.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 32.05% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $22.4 million (down 84.33% YoY), while the FY2025 annual figure was $20.7 million, down 85.51% from the prior year.
- Operating Expenses declined to $6.9 million in Q1 2026 per TRAW's latest filing, from $7.4 million in the prior quarter.
- Across five years, Operating Expenses topped out at $123.4 million in Q2 2024 and bottomed at $4.0 million in Q2 2025.
- Historically, Operating Expenses has averaged $12.4 million across 5 years, with a median of $5.3 million in 2024.
- Annual changes were most pronounced in 2024 — Operating Expenses jumped 2544.2% — and 2025, when it tumbled 96.77%.
- Traws Pharma's Operating Expenses stood at $5.8 million in 2022, then declined by 21.97% to $4.5 million in 2023, then rose by 18.06% to $5.3 million in 2024, then soared by 38.13% to $7.4 million in 2025, then slipped by 5.73% to $6.9 million in 2026.
- Business Quant data shows TRAW's Operating Expenses at $6.9 million in Q1 2026, $7.4 million in Q4 2025, and $4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Traws Pharma | 5.60 Mn | 588,417.40 | - | 3.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.95 Mn |
| Dec 31, 2025 | 7.37 Mn |
| Sep 30, 2025 | 4.06 Mn |
| Jun 30, 2025 | 3.98 Mn |
| Mar 31, 2025 | 5.26 Mn |
| Dec 31, 2024 | 5.33 Mn |
| Sep 30, 2024 | 8.59 Mn |
| Jun 30, 2024 | 123.41 Mn |
| Mar 31, 2024 | 5.27 Mn |
| Dec 31, 2023 | 4.52 Mn |
| Sep 30, 2023 | 5.15 Mn |
| Jun 30, 2023 | 4.67 Mn |
| Mar 31, 2023 | 6.19 Mn |
| Dec 31, 2022 | 5.79 Mn |
| Sep 30, 2022 | 5.70 Mn |
| Jun 30, 2022 | 4.18 Mn |
| Mar 31, 2022 | 4.19 Mn |
| Dec 31, 2021 | 3.82 Mn |
| Sep 30, 2021 | 4.05 Mn |
| Jun 30, 2021 | 4.70 Mn |